Company Overview
CareDx, Inc. operates within the healthcare sector, specifically focusing on diagnostics and research, where it delivers specialized solutions designed to improve outcomes for transplant patients and advance organ health globally. The company's core offerings include AlloSure Kidney, a donor-derived cell-free DNA solution for kidney transplant patients, and AlloMap Heart, a gene expression-based diagnostic tool for heart health monitoring. In terms of scale, CareDx, Inc. holds a market capitalization of $917.56M and reported annual revenue of $379.80M for the trailing twelve months, supporting a workforce of 761 employees. These valuation and revenue figures indicate that the company maintains a substantial presence in the medical diagnostics industry, reflecting significant market confidence despite its current profitability challenges.
Financial Health
CareDx, Inc. generated revenue of $379.80M over the trailing twelve months, while reporting a net income of $-21,354,000 and an EBITDA of $-7,795,000. The substantial gap between the $379.80M revenue and the -$21,354,000 net income reveals a cost structure characterized by high operational expenses or one-time charges that significantly erode bottom-line profitability. Notably, the company generated positive free cash flow of $45.75M, which provides essential financial flexibility to fund operations, invest in research and development, or reduce debt without immediate reliance on external capital markets. The company's margins show a gross margin of 67.6%, indicating strong pricing power or low cost of goods sold, contrasted sharply by an operating margin of -3.5% and a profit margin of -5.6% which highlight the heavy burden of operating costs. The balance sheet presents a mix of liquidity and leverage, holding $177.21M in cash against $26.19M in debt, supported by a debt-to-equity ratio of 8.64 which suggests a leveraged position reliant on equity rather than creditor financing. Liquidity remains robust with a current ratio of 2.86, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities. However, return metrics such as a return on equity of -6.3% and a return on assets of -3.2% reveal that management effectiveness has been hindered by losses, resulting in negative returns on the capital base and total assets respectively.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to recent losses, while the forward P/E stands at 16.34, implying that the market prices in a significant expected turnaround in earnings trajectory over the coming year. The price-to-book ratio is recorded at 3.00, suggesting that the market values the company at three times its book value, which often indicates a premium assigned to the company's intangible assets, growth potential, or proprietary technology. Alternative valuation measures further define the investment profile, with a price-to-sales ratio of 2.42 and an EV/EBITDA of -97.84, the latter reflecting the current negative earnings before interest, taxes, depreciation, and amortization status. The stock has exhibited significant volatility, trading between a 52-week high of $21.48 and a 52-week low of $10.96, a range that defines the historical price boundaries for the security. With a beta of 2.58, the stock demonstrates high sensitivity to market movements, meaning it is expected to be 2.58 times more volatile than the broader market index.
Growth & Income
The company demonstrated robust top-line expansion with revenue growth of 25.2% year-over-year, whereas earnings growth is listed as N/A due to the lack of net income in the current period. The absence of positive earnings growth relative to revenue highlights that the expansion of sales has not yet translated into proportional profit increases, likely due to the fixed cost structure or ongoing investment phases. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that it reinvests all available cash flows and earnings back into the business rather than distributing income to shareholders. This reinvestment strategy is typical for growth-oriented biotech or diagnostic firms that prioritize scaling their product portfolio over providing immediate income returns. The overall growth and income profile is characterized by accelerating revenue generation but constrained profitability, with no current income distribution to shareholders.